Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Seaport Res Ptn issued their Q1 2026 earnings per share (EPS) estimates for Curaleaf in a report released on Wednesday, March 5th. Seaport Res Ptn analyst S. Randhawa forecasts that the company will earn ($0.06) per share for the quarter. The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Seaport Res Ptn also issued estimates for Curaleaf's Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.19) EPS.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.09. Curaleaf had a negative net margin of 14.82% and a negative return on equity of 13.67%. The business had revenue of $331.05 million for the quarter, compared to analyst estimates of $331.87 million.
Curaleaf Price Performance
Shares of CURLF traded down $0.03 during mid-day trading on Friday, hitting $0.96. The company's stock had a trading volume of 556,236 shares, compared to its average volume of 744,790. The company has a current ratio of 1.11, a quick ratio of 0.51 and a debt-to-equity ratio of 0.85. Curaleaf has a 1-year low of $0.88 and a 1-year high of $6.40. The firm has a market capitalization of $634.20 million, a P/E ratio of -3.31 and a beta of 0.57. The firm has a 50-day simple moving average of $1.41 and a 200 day simple moving average of $2.13.
About Curaleaf
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Articles
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
